MV-CEA

MV-CEA is a recombinant oncolytic measles virus (derived from the Edmonston vaccine strain, MV-Edm) engineered to express the soluble extracellular domain of human carcinoembryonic antigen (CEA). The expressed CEA serves as a tumor-associated marker that can be detected in serum, allowing for non-invasive monitoring of viral gene expression and treatment response. MV-CEA selectively infects and kills tumor cells due to their high expression of CD46, which facilitates viral entry, while sparing normal cells with low CD46 density. Its mechanism involves direct oncolysis through syncytia formation and induction of proinflammatory changes in the tumor microenvironment. Clinical trials have evaluated its safety and preliminary efficacy in recurrent glioblastoma multiforme (GBM), ovarian cancer confined to the peritoneal cavity, oligodendroglioma, peritoneal neoplasms, and preclinical studies suggest potential utility in prostate cancer. No dose-limiting toxicities have been observed up to maximum tested doses; treatment has shown disease stabilization and favorable survival outcomes compared with historical controls[1][4][5][6][8].

Other names

carcinoembryonic antigen-expressing measles virusmeasles virus derivative producing cea